Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma
复制标题
DOI：
10.1007/s10147-012-0411-y
复制
发表时间：
2013-06-01
影响因子：
3.3
通讯作者：
Uhara, Hisashi
中科院分区：
文献类型：
--
作者：
Nakamura, Kenta;Okuyama, Ryuhei;Uhara, Hisashi
由于转移性皮肤鳞状细胞癌（CSCC）是罕见的，标准化疗尚未完全建立。在日本，铂类和蒽环类联合化疗因其低毒性而被用于晚期CSCC老年患者。然而，这种疗法的临床效益还没有得到充分的examined.We回顾性研究了铂类和蒽环类联合化疗转移性CSCC的反应率。8例患者接受联合化疗转移病灶，有淋巴结病变6例，皮肤和肺部病变各1例。联合方案如下：顺铂（CDDP）（60-90 mg/m2/天，第1天）和阿霉素（ADM）（20-40 mg/m2/天，第1天或第2天）; CDDP（10- 1 - 5 mg/m2/天，第1-5天）和表阿霉素（epi-ADM）（10-15 mg/m2/d，第1-5天）;卡铂（CBDCA）200-400 mg/m2/d，第1天;阿霉素（ADM）20-40 mg/m2/d，第1或2天。答复如下：2例患者完全缓解（CDDP + ADM治疗肺转移，CDDP + epi-ADM治疗淋巴结转移），1例患者部分缓解（CDDP + ADM治疗淋巴结转移），2例患者病情稳定，3例患者病情进展。在2例显示完全缓解的患者中观察到持久缓解（58个月和112个月）。尽管2例患者显示持久完全缓解，但铂类和蒽环类联合治疗转移性CSCC的临床效果有限。
Because metastatic cutaneous squamous cell carcinoma (CSCC) is rare, standard chemotherapy has not been fully established. In Japan, combination platinum and anthracycline chemotherapy has been used for elderly patients with advanced CSCC because of its low toxicity. However, the clinical benefit of this therapy has not been fully examined.We retrospectively examined the response rate of combination platinum and anthracycline chemotherapy for metastatic CSCC.Eight patients received combination chemotherapy for metastatic lesions; there were lymph node lesions in 6 patients and skin and lung lesions in one patient each. The combination regimens were as follows: cisplatin (CDDP) (60-90 mg/m(2)/day, day 1) and adriamycin (ADM) (20-40 mg/m(2)/day, day 1 or 2) was administered in 5 patients; CDDP (10-15 mg/m(2)/day, days 1-5) and epirubicin (epi-ADM) (10-15 mg/m(2)/day, days 1-5) was administered in 2 patients; and carboplatin (CBDCA) (200-400 mg/m(2)/day, day 1) and ADM (20-40 mg/m(2)/day, day 1 or 2) was administered in one patient. The responses were as follows: complete response in 2 patients (CDDP + ADM for lung metastasis, CDDP + epi-ADM for lymph node metastasis), partial response in 1 (CDDP + ADM for lymph node metastasis), stable disease in 2, and progressive disease in 3. A durable response was observed in 2 patients showing complete responses (58 and 112 months).The clinical effect of the combination of platinum and anthracycline for metastatic CSCC was limited despite the findings of two patients showing durable complete responses.